MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-21-00254

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021

Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture.

Brinkmann Christina, Abdel-Wahab Mohamed, Bedogni Francesco, Bhadra Oliver Daniel, Charbonnier Gaetan, Conradi Lenard, Hildick-Smith David, Kargoli Faraj, Latib Azeem, Van Mieghem Nicolas M, Mylotte Darren, Landes Uri, Pilgrim Thomas, Stripling Jan, Taramasso Maurizio, Tchétché Didier, Testa Luca, Thiele Holger, Webb John, Windecker Stephan, Witt Julian, Wohlmuth Peter, Schofer Joachim

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Bioprosthetic valve fracture (BVF) is a technique to reduce gradients in valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) procedures. The outcome of VIV-TAVI with BVF has not been compared with VIV-TAVI without BVF.

AIMS: The aim of this study was to evaluate the outcome of VIV-TAVI with BVF compared to VIV-TAVI without BVF.

METHODS

In total, 81 cases of BVF VIV-TAVI (BVF group) from 14 centres were compared to 79 cases of VIV-TAVI without BVF (control group).

RESULTS

VARC-2-defined device success was 93% in the BVF group and 68.4% in the control group (p<0.001). The mean transvalvular gradient decreased from 37±13 mmHg to 10.8±5.9 mmHg (p<0.001) in the BVF group and from 35±16 mmHg to 15.8±6.8 mmHg (p<0.001) in the control group with a significantly higher final gradient in the control group (p<0.001). The transvalvular gradients did not change significantly over time. In-hospital major adverse events occurred in 3.7% in the BVF group and 7.6% in the control group (p=0.325). A linear mixed model identified BVF, self-expanding transcatheter heart valves (THVs) and other surgical aortic valve (SAV) types other than Mitroflow as predictors of lower transvalvular gradients.

CONCLUSIONS

Compared to VIV-TAVI alone, VIV-TAVI with BVF resulted in a significantly lower transvalvular gradient acutely and at follow-up. Independent predictors of lower gradients were the use of self-expanding THVs and the treatment of SAVs other than Mitroflow, irrespective of BVF performance. BVF significantly reduced the gradient independently from transcatheter or surgical valve type.

Для цитирования: Brinkmann Christina, Abdel-Wahab Mohamed, Bedogni Francesco, Bhadra Oliver Daniel, Charbonnier Gaetan, Conradi Lenard, Hildick-Smith David, Kargoli Faraj, Latib Azeem, Van Mieghem Nicolas M, Mylotte Darren, Landes Uri, Pilgrim Thomas, Stripling Jan, Taramasso Maurizio, Tchétché Didier, Testa Luca, Thiele Holger, Webb John, Windecker Stephan, Witt Julian, Wohlmuth Peter, Schofer Joachim. Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2021. DOI: 10.4244/eij-d-21-00254.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.